CGTN: China to build Zhejiang into demonstration zone for common prosperity

BEIJING, June 13, 2021 /PRNewswire/ — China’s eastern Zhejiang province is expected to make substantial progress in building a demonstration zone for common prosperity through high-quality development, according to a guideline released by the Communist Party of China Central Committee…

Marcus Ericsson, Honda Win Opening Round of Detroit Doubleheader

DETROIT, June 12, 2021 /PRNewswire/ — Taking advantage of a late-race mechanical problem for Will Power, Chip Ganassi Racing’s Marcus Ericsson leapt to the front of the field following the second of two red flag race stoppages to win the opening round of the Detroit Grand Prix NTT…

Inauguração da Franquia PowerLook em Manaus é um sucesso

MANAUS, Brasil, 12 de junho de 2021 /PRNewswire/ — Chegou em Manaus na última quinta-feira, 10 de junho, a franquia carioca de locação de vestidos e roupas para todas as ocasiões, e a marca chegou com tudo. Com a presença de Flavia Sampaio, CEO e fundadora da marca, Manaus brilhou. A…

Inauguração da Franquia PowerLook em Manaus é um sucesso

MANAUS, Brasil, 12 de junho de 2021 /PRNewswire/ — Chegou em Manaus na última quinta-feira, 10 de junho, a franquia carioca de locação de vestidos e roupas para todas as ocasiões, e a marca chegou com tudo. Com a presença de Flavia Sampaio, CEO e fundadora da marca, Manaus brilhou. A…

Amenazada la paquetería que envían los colombianos desde el exterior

MIAMI, 12 de junio de 2021 /PRNewswire-HISPANIC PR WIRE/ — Hace un par de meses, Jennifer Holguín, Consultora de Mohr World Consulting, empresa radicada en Miami desde 2001, inició un estudio comisionado por ICSA (International Courier Services Association), la asociación que reúne las…

Did You Acquire (QS) Before November 27, 2020? Johnson Fistel Investigates QuantumScape; Should Management be Held Accountable for Investors Losses?

SAN DIEGO, June 12, 2021 /PRNewswire/ — Johnson Fistel, LLP is investigating potential claims on behalf of QuantumScape Corporation (“QuantumScape” or the “Company”) (NYSE: QS) against certain of its officers and directors. Recently a class action lawsuit was filed in federal court…

China to deepen reform, opening-up, expand cooperation in new era

BEIJING, June 12, 2021 /PRNewswire/ — With the conviction that openness is the way to growth and wealth, Chinese President Xi Jinping has called on China and the rest of the world to expand cooperation and build a community with a shared future for mankind. While attending the APEC CEO…

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab…

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

RARITAN, N.J., June 12, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a…

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia

RARITAN, N.J., June 12, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab…

« Previous PageNext Page »